In this segment, the panel highlights the growing therapeutic pipeline in Sjögren’s Disease (SjD), emphasizing that multiple investigational agents are now targeting distinct immune pathways. They discuss dazodalibep, a non–B-cell-depleting CD40–CD40L inhibitor shown in recent trials to improve systemic disease activity, dryness, and fatigue while maintaining a favorable safety profile. The panel then reviews FcRn inhibitors, including nipocalimab and efgartigimod, which work by reducing circulating IgG autoantibodies—an approach that may be particularly beneficial for patients with high autoantibody-driven disease.

They also cover telitacicept, a dual BAFF/APRIL inhibitor that targets B-cell and plasma cell survival pathways, showing promising phase 3 results in patients with systemic features such as hypergammaglobulinemia and glandular swelling. Finally, they discuss deucravacitinib, a TYK2 inhibitor that modulates type I interferon and IL-12/23 signaling, pathways strongly implicated in SjD gene expression profiles. The panel expresses optimism that these diverse mechanisms may allow more personalized, biomarker-driven treatment strategies moving forward.